Stockscreener 앱 받기
9.64
7.83%
0.70
시간 외 거래:
9.62
-0.02
-0.21%
전일 마감가:
$8.94
열려 있는:
$9.19
하루 거래량:
7.39M
Relative Volume:
2.43
시가총액:
$2.11B
수익:
$52.04M
순이익/손실:
$-290.50M
주가수익비율:
-6.6222
EPS:
-1.4557
순현금흐름:
$-240.94M
1주 성능:
+10.30%
1개월 성능:
+5.24%
6개월 성능:
-29.74%
1년 성능:
+16.14%
1일 변동 폭
$8.62
$9.745
1주일 범위
$8.57
$9.745
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.64 | 1.97B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan - Investing.com Nigeria
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan By Investing.com - Investing.com South Africa
Director at Ocular Therapeutix (OCUL) receives RSUs and stock options - Stock Titan
Ocular Therapeutix (OCUL) director granted RSUs and options in new equity awards - Stock Titan
Ocular Therapeutix (OCUL) CFO awarded RSUs and stock options in new equity grant - Stock Titan
Ocular Therapeutix (OCUL) director receives 14,000 RSUs and 44,000 stock options - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) director receives RSU and option grants - Stock Titan
Ocular Therapeutix (OCUL) director granted RSUs and 44,000 stock options - Stock Titan
Ocular Therapeutix (OCUL) director receives new RSU and stock option awards - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) expands stock plan and names new CFO - Stock Titan
Ocular Therapeutix, Inc. Appoints Jason Robins as Chief Financial Officer - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Ocular Therapeutix Inc Annual Shareholders Meeting Transcript - GuruFocus
OCUL Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock HigherGuidance vs Actual - newsline.com
Ocular Therapeutix (OCUL) Edges Lower, Testing Key Support ZoneStandard Deviation - newsline.com
(OCUL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Ocular Therapeutix CMO Nadia Waheed sells $122k in shares - Investing.com UK
Ocular Therapeutix CMO Nadia Waheed sells $122k in shares By Investing.com - Investing.com South Africa
Ocular Therapeutix (OCUL) CMO auto-sells 14,828 shares for taxes - Stock Titan
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Yahoo Finance
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix, Inc. to Participate in Clinical Trials at the Summit 2026 in Las Vegas - Quiver Quantitative
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026 - The Manila Times
Ocular Therapeutix to detail OTX-TKI trial outcomes at Vegas retina summit - Stock Titan
OCUL (NASDAQ: OCUL) Form 144 — 14,828 restricted shares vesting - Stock Titan
OCUL Technical Analysis | Trend, Signals & Chart Patterns | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix™ to Host Investor Day on June 17, 2026 - GlobeNewswire
Ocular Therapeutix (OCUL) Valuation Check After Recent Trading And AXPAXLI Growth Expectations - Sahm
Ocular Therapeutix Stock Hits Day High with Strong 7.14% Intraday Surge - Markets Mojo
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix CDO Peter Kaiser sells $24,329 in stock By Investing.com - Investing.com India
Ocular Therapeutix chief scientific officer sells $24,747 in stock By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief scientific officer sells $24,747 in stock - Investing.com
Ocular Therapeutix CDO Peter Kaiser sells $24,329 in stock - Investing.com
Liquidity Mapping Around (OCUL) Price Events - Stock Traders Daily
Automatic tax-driven sale and trust transfer by Ocular (OCUL) insider - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) CDO executes 2,967-share tax sell-to-cover trade - Stock Titan
Ocular Therapeutix (OCUL) CSO sells 3,018 shares to cover RSU taxes - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) CSO auto-sells 1,858 shares for tax obligations - Stock Titan
Ocular Therapeutix, Inc. (OCUL) Latest Stock News & Headlines - Yahoo Finance
OCUL Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressLow Estimate Range - newsline.com
Ocular Therapeutix (OCUL) Rises 3% as Investor Sentiment StrengthensBear Flag - newsline.com
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 - The Motley Fool
Morgan Stanley (NASDAQ: OCUL) files Rule 144 notice to sell 1,858 shares - Stock Titan
Company (NASDAQ: OCUL) files Form 144 to sell 2,967 shares - Stock Titan
OCUL (NASDAQ: OCUL) files Form 144 proposing sale of 3,018 shares - Stock Titan
Rule 144 notice for 21,156 shares — OCUL (OCUL) - Stock Titan
Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):